BIOMAT Database Logo BIOMAT Database Logo

alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. 1991

X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
University of Athens Medical School, Laikon General Hospital, Greece.

The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 x 10(9)/L was achieved in 94%, and below 400 x 10(9)/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
June 1989, British journal of haematology,
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
January 1989, Blut,
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Treatment of essential thrombocythaemia with interferon alpha-2b.
January 1989, Lancet (London, England),
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Treatment of essential thrombocythaemia by alpha-interferon.
September 1988, Lancet (London, England),
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
May 1989, The American journal of medicine,
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
[Alpha interferon treatment of chronic myeloproliferative disease associated thrombocytosis].
January 1993, Duodecim; laaketieteellinen aikakauskirja,
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Treatment of essential thrombocythaemia by alpha 2a interferon.
October 1988, Lancet (London, England),
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b.
January 1991, European journal of cancer (Oxford, England : 1990),
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon.
November 1994, British journal of haematology,
X Yataganas, and J Meletis, and E Plata, and N Viniou, and F Deligiannis, and C Tsekoura, and E Voscaridou, and V Boussiotis, and J Rombos, and G Vayopoulos
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.
January 1985, Oncology,
Copied contents to your clipboard!